Actos (Pioglitazone) Label Updates 2020 to 2026: FDA Safety Changes, Warnings, and Clinical Context

Pioglitazone (brand name Actos) is an oral thiazolidinedione (TZD) that received FDA approval in 1999 for treating type 2 diabetes. As a PPAR-gamma agonist, it enhances insulin sensitivity across muscle and adipose tissue by a mechanism distinct from insulin secretion stimulation. Since 2012, generic formulations have dominated clinical use and now represent the predominant form dispensed to patients.

Direct answer: Pioglitazone's FDA label has not gained a new indication or a new boxed warning between 2020 and 2026. The label still carries a boxed warning for congestive heart failure, still carries cautionary bladder cancer language despite a large observational study that did not find a statistically significant association, and still describes an elevated distal-limb fracture risk in women. The most concrete labeling change in this period was a 2023-era simplification of liver enzyme monitoring language and clearer dose-capping guidance when pioglitazone is combined with gemfibrozil. Pioglitazone remains approved only for glycemic control in type 2 diabetes; its use for NASH/MASH (metabolic dysfunction-associated steatohepatitis) is off-label, regardless of supportive trial data.

This article draws on the current FDA-approved prescribing information, FDA drug safety communications, and the FDA's public description of its Sentinel surveillance program. Several specific effect sizes and trial statistics that circulate around pioglitazone (bladder cancer hazard ratios, PROactive and IRIS trial results, PIVENS histologic response rates) are widely cited in secondary sources, but the identifiers commonly attached to them could not be independently verified for this draft. Where that is the case, the finding is described directionally and flagged for verification against the primary publication rather than presented as a precise, load-bearing number.

What is established, what is plausible, and what is not established

Established (label and FDA communications):

• Boxed warning for congestive heart failure; contraindicated in NYHA Class III/IV heart failure.
• Bladder cancer caution language remains in the label; a 2011 FDA safety communication raised the signal, and the FDA later softened its restriction on prescribing to patients with a bladder cancer history, without removing all cautionary language (FDA Drug Safety Communication, 2011).
• Fracture risk in women is described in the label as elevated relative to placebo.
• Pioglitazone is metabolized substantially through CYP2C8, and gemfibrozil (a strong CYP2C8 inhibitor) meaningfully raises pioglitazone exposure, warranting a lower maximum dose.
• Pioglitazone has no FDA-approved indication for NASH or MASH.

Plausible but not settled by the sources reviewed here:

• The magnitude of cardiovascular benefit or harm relative to other second-line diabetes drugs (sulfonylureas, DPP-4 inhibitors). Directionally suggestive data exist from older trials, but exact hazard ratios attributed to specific FDA Sentinel analyses could not be verified in this draft and should not be quoted as precise figures without checking the primary Sentinel report or a published Sentinel analysis.
• The exact bladder cancer point estimate from long-term observational follow-up. A large observational study is widely referenced as reassuring but not fully exculpatory; the specific hazard ratio commonly cited needs verification against the original journal article before it is used in patient-facing material.

Not established:

• A cardiovascular benefit indication for pioglitazone. Unlike some GLP-1 receptor agonists and SGLT-2 inhibitors, pioglitazone's label has not been expanded to include a cardiovascular risk reduction claim.
• Any FDA-recognized role for pioglitazone in treating NASH/MASH. Guideline bodies may discuss pioglitazone as an option in specific patient subgroups, but that is guideline-level, off-label use, not an approved indication.

The bladder cancer warning: what changed and what did not

In 2011 the FDA issued a drug safety communication describing a possible increased bladder cancer risk with pioglitazone use beyond about 12 months, based on interim data from an observational study the agency had required as a post-marketing commitment (FDA, 2011). Longer-term follow-up from that same observational program is widely reported as not showing a statistically significant increase in bladder cancer risk, which is why the FDA later removed its recommendation against prescribing pioglitazone to patients with an active or recent history of bladder cancer.

What this means for prescribing in 2026: the label retains cautionary language, not because the signal was confirmed, but because the agency has not concluded the question is fully closed. A point estimate above 1.0, even without statistical significance, is a reason for continued monitoring and shared decision-making with patients who have risk factors for bladder cancer (smoking history, prior hematuria, prior urothelial disease), not a reason for reflexive avoidance in an otherwise good candidate.

Heart failure: the warning that has not moved

The congestive heart failure boxed warning has been part of the pioglitazone label since 2007 and was unchanged through the 2020 to 2026 period reviewed here. Pioglitazone causes dose-dependent fluid retention through renal sodium reabsorption effects related to PPAR-gamma activation, and this can precipitate or worsen heart failure. The label contraindicates use in NYHA Class III or IV heart failure and calls for monitoring for signs of fluid overload (rapid weight gain, edema, dyspnea) in all patients started on the drug, including those without known heart failure at baseline.

This warning is the single most important reason pioglitazone is not first-line therapy for patients with existing heart failure or significant cardiac risk, regardless of how favorably its glycemic or metabolic profile compares with alternatives.

Fracture risk in women: what the label change means for screening

Randomized trial pooling has shown an increased rate of distal limb fractures (hand, foot, wrist, upper arm) in women taking pioglitazone compared with placebo, with the label specifying this applies regardless of menopausal status. Men have not shown a comparable signal in the pooled data. The mechanism is thought to involve PPAR-gamma-mediated suppression of osteoblast activity, shifting bone marrow stem cell differentiation toward fat cells rather than bone-forming cells.

The practical implication: postmenopausal women, and premenopausal women with other fracture risk factors, are reasonable candidates for a baseline fracture risk conversation, and DEXA screening before starting pioglitazone is a defensible clinical judgment call in higher-risk patients, consistent with the direction of professional society guidance in this space, even though the exact screening protocol is a clinical judgment rather than a labeled requirement.

Liver monitoring: the 2023-era simplification

Pioglitazone's original label required liver enzyme testing every two months during the first year of treatment. That requirement was inherited from the class-wide caution created by troglitazone (Rezulin), an earlier thiazolidinedione withdrawn from the market in 2000 after being linked to fatal liver failure. Pioglitazone itself has not shown that hepatotoxicity signal across more than two decades of use.

The current label reflects a more flexible approach: check ALT at baseline, then periodically based on clinical judgment rather than a fixed calendar, with a clear instruction to stop pioglitazone if ALT rises above three times the upper limit of normal. This is a meaningful simplification for primary care prescribers, but it is not a statement that liver monitoring is unnecessary. Patients with pre-existing liver disease, alcohol use, or other hepatotoxic drug exposure still warrant closer follow-up as a matter of clinical judgment.

The gemfibrozil interaction and the 15 mg ceiling

Pioglitazone is metabolized primarily through CYP2C8. Gemfibrozil, a fibrate used for triglyceride management, is a strong inhibitor of that enzyme and substantially raises pioglitazone blood levels when the two are taken together. Current prescribing information caps pioglitazone at 15 mg daily when gemfibrozil is co-administered. This is a concrete, actionable interaction: any patient on both drugs, or being started on either while already taking the other, needs a dose review rather than a default assumption that standard dosing applies.

MASH/NASH: real trial signal, no FDA indication

A randomized trial published in 2010 (commonly referenced as the PIVENS trial) compared pioglitazone, vitamin E, and placebo in nondiabetic adults with biopsy-confirmed NASH and reported meaningful histologic improvement with pioglitazone relative to placebo. Liver guideline bodies have subsequently listed pioglitazone as a treatment option for biopsy-proven NASH in some patients, with or without type 2 diabetes.

None of this has translated into an FDA-approved MASH indication for pioglitazone, and the manufacturer has not pursued a supplemental application for it. In 2024 the FDA approved resmetirom (Rezdiffra) as the first drug specifically indicated for noncirrhotic MASH with moderate to advanced fibrosis (FDA press release, March 14, 2024). That approval did not trigger any labeling change for pioglitazone. Any current use of pioglitazone for NASH/MASH is off-label, and clinicians and patients considering it should treat it that way explicitly, including documenting the off-label rationale and the availability of an FDA-approved alternative.

Why pioglitazone's label did not expand the way GLP-1 and SGLT-2 labels did

During the same period, several GLP-1 receptor agonists and SGLT-2 inhibitors gained label expansions for cardiovascular risk reduction, heart failure, and chronic kidney disease, based on dedicated outcome trials designed and powered for those endpoints. Pioglitazone's cardiovascular evidence base is older, comes from a single large outcomes trial from the mid-2000s whose primary endpoint did not reach statistical significance, and has not been followed by a modern dedicated cardiovascular outcomes trial. Generic manufacturers, who now supply essentially all pioglitazone sold, have no commercial incentive to fund the kind of large trial that would be needed to support a label expansion. The result is a structural, not necessarily scientific, reason pioglitazone's label has stayed narrower than newer diabetes drug classes.

Current label status as of the most recent revision on file

Based on the FDA-accessible prescribing information (Actos label, Takeda, revised 2025):

• Boxed warning: congestive heart failure, unchanged since 2007.
• Contraindications: NYHA Class III/IV heart failure, known hypersensitivity to pioglitazone.
• Warnings and precautions: cardiac failure and edema, hepatic effects, fractures, macular edema, bladder cancer, resumption of ovulation in premenopausal anovulatory women, hypoglycemia risk when combined with insulin or sulfonylureas.
• Approved indication: adjunct to diet and exercise for glycemic control in type 2 diabetes, as monotherapy or in combination with other antidiabetic agents.
• Dosing: 15 mg or 30 mg once daily, up to a maximum of 45 mg once daily; maximum 15 mg once daily with concomitant gemfibrozil.

Because labels are revised on their own schedule and this description reflects the most recent revision available at the time of writing, prescribers should confirm current label language directly before making a prescribing decision based on any specific detail above.

A decision framework: is pioglitazone a reasonable choice for this patient right now

This framework does not replace clinical judgment tailored to individual patients and carries no dosing recommendations. Rather, it provides a systematic approach to identify regulatory labeling constraints that warrant consideration before relying on a drug's low cost and generic status as the primary rationale for selection.

Step 1: Rule out the boxed-warning contraindication. Does the patient have NYHA Class III or IV heart failure, or a history of decompensated heart failure with reduced ejection fraction? If yes, pioglitazone is contraindicated regardless of glycemic or cost benefits. Move to a different drug class.

Step 2: Screen for fluid-sensitive conditions even without formal heart failure. Significant peripheral edema at baseline, uncontrolled hypertension with volume sensitivity, or borderline cardiac reserve all raise the practical risk of the fluid-retention effect, even in patients who do not meet a formal heart failure diagnosis. This is a reason for closer monitoring, not automatic exclusion.

Step 3: Assess bladder cancer risk factors. Active or recent bladder cancer history warrants a specific conversation about the residual, unresolved signal, even though the current restriction against use in this group has been relaxed. Smoking history and prior hematuria raise the threshold for using pioglitazone as a default choice, though they do not make it categorically inappropriate.

Step 4: For women, assess fracture risk before starting, not after a fracture. Postmenopausal status plus any additional risk factor (low body weight, prior fragility fracture, glucocorticoid use, osteoporosis diagnosis) is a reasonable trigger for a baseline bone density conversation or DEXA referral before initiation, not after several years of therapy.

Step 5: Check the drug list for CYP2C8 interactions. Gemfibrozil specifically requires capping pioglitazone at 15 mg daily. Any fibrate or other CYP2C8 inhibitor on the medication list should trigger a pharmacist or prescriber review before dosing.

Step 6: If the indication under discussion is NASH/MASH rather than diabetes, treat it as off-label from the start. Document that the FDA-approved indication is limited to glycemic control, that resmetirom is the FDA-approved option for MASH with fibrosis, and that pioglitazone's use for liver disease rests on older trial data and guideline mention rather than an approved label claim. This does not mean pioglitazone cannot be used for MASH; it means the off-label status and the FDA-approved alternative should be part of the conversation with the patient.

Step 7: Reassess liver monitoring frequency based on the individual, not a fixed calendar. Baseline ALT is still reasonable for everyone starting pioglitazone. Patients with pre-existing liver disease, heavy alcohol use, or other hepatotoxic exposures warrant more frequent follow-up than the label's minimum; stable patients with normal baseline liver function do not need enzyme checks every two months.

If a patient clears steps 1 through 4 without a major flag, pioglitazone remains one of the least expensive and best-studied second-line options for type 2 diabetes, with the caveat that "well-studied" here means decades of real-world use and one older outcomes trial, not a modern cardiovascular outcomes trial of the kind newer diabetes drugs now carry.

When to seek urgent evaluation

Patients on pioglitazone who develop sudden shortness of breath, rapid weight gain, significant new leg swelling, visible blood in the urine, or new visual changes should be evaluated promptly rather than waiting for a routine follow-up appointment. These findings can reflect fluid overload, a bladder-related process, or macular edema, all of which are recognized concerns tied to this drug and warrant timely, rather than routine, evaluation.